You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased.
Lexent's technology integrates low-pass whole-genome sequencing, fragmentomics, and DNA methylation to detect early stage disease.
By combining with ArcherDX, Invitae will gain tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response.
The firm expects to launch a tissue-based immunohistochemistry version of the test, which detects QSOX1, in mid-2021, followed by a dipstick plasma-based assay by early 2022.
Lexent Bio's monitoring platform is in development and based on low-pass whole-genome sequencing and DNA methylation analysis.
Private equity firms KKR and Ampersand Capital have reportedly proposed acquiring Oxford Immunotec for around $15 per share in cash.
Finland-based Medix Biochemica said the acquisition of US-based EastCoast Bio broadens its antibody and antigen offering in several diagnostic areas.
UrSure is developing and commercializing products that measure adherence to HIV medications, including pre-exposure prophylaxis, or PrEP.
Roche said the acquisition is expected to advance development of its nanopore sequencer by providing access to Stratos' Sequencing by Expansion chemistry.
The two organizations announced a partnership earlier this year to manufacture and process Curative's oral fluid-based SARS-CoV-2 test.